
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 GeneNews Corporation, Toronto, Canada; 2 Department of Anatomical and Cellular Pathology, Chinese University of Hong Kong, Hong Kong, China; 3 Lam Wah Ee Hospital, Penang, Malaysia; 4 Department of Digestive Medicine, 2nd Affiliated Hospital of Medical College of Zhejiang University; 5 Department of Colorectal Surgery, 1st Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, China; 6 Department of Surgery, 1st Affiliated Hospital, Anhui Medical University, Hefei, China; and 7 Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
Requests for reprints: Choong Chin Liew, GeneNews Corporation, 2 East Beaver Creek Road, Building 2, Richmond Hill, Ontario, Canada L4B 2N3. Phone: 617-834-4371; E-mail: cliew{at}genenews.com.
Purpose: We applied a unique method to identify genes expressed in whole blood that can serve as biomarkers to detect colorectal cancer (CRC).
Experimental Design: Total RNA was isolated from 211 blood samples (110 non-CRC, 101 CRC). Microarray and quantitative real-time PCR were used for biomarker screening and validation, respectively.
Results: From a set of 31 RNA samples (16 CRC, 15 controls), we selected 37 genes from analyzed microarray data that differed significantly between CRC samples and controls (P < 0.05). We tested these genes with a second set of 115 samples (58 CRC, 57 controls) using quantitative real-time PCR, validating 17 genes as differentially expressed. Five of these genes were selected for logistic regression analysis, of which two were the most up-regulated (CDA and MGC20553) and three were the most down-regulated (BANK1, BCNP1, and MS4A1) in CRC patients. Logit (P) of the five-gene panel had an area under the curve of 0.88 (95% confidence interval, 0.81-0.94). At a cutoff of logit (P) >+0.5 as disease (high risk), <–0.5 as control (low risk), and in between as an intermediate zone, the five-gene biomarker combination yielded a sensitivity of 94% (47 of 50) and a specificity of 77% (33 of 43). The intermediate zone contained 22 samples. We validated the predictive power of these five genes with a novel third set of 92 samples, correctly identifying 88% (30 of 34) of CRC samples and 64% (27 of 42) of non-CRC samples. The intermediate zone contained 16 samples.
Conclusion: Our results indicate that the five-gene biomarker panel can be used as a novel blood-based test for CRC.
This article has been cited by other articles:
![]() |
V. Melotte, M. H. F. M. Lentjes, S. M. van den Bosch, D. M. E. I. Hellebrekers, J. P. J. de Hoon, K. A. D. Wouters, K. L. J. Daenen, I. E. J. M. Partouns-Hendriks, F. Stessels, J. Louwagie, et al. N-Myc Downstream-Regulated Gene 4 (NDRG4): A Candidate Tumor Suppressor Gene and Potential Biomarker for Colorectal Cancer J Natl Cancer Inst, July 1, 2009; 101(13): 916 - 927. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Morello, D Schiavone, G Mengozzi, C Bertello, C C Liew, D Bisbocci, P Mulatero, and F Veglio Adrenal endothelin-1 levels are not associated with aldosterone secretion in primary aldosteronism Eur. J. Endocrinol., March 1, 2009; 160(3): 453 - 458. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |